Galectin Therapeutics, Inc. GALTW 深 滬
交易中 09-09 10:20:34 美东时间
0.0425
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0425
- 總市值 0
- 52周最高 0.254
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.024
- 委 比 0.00%
- 總股本 --
- 歷史最高 0.254
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.024
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galectin Therapeutics Highlights Promising Belapectin Results
An update from Galectin Therapeutics ( ($GALT) ) is now available. On September...
09-08 20:21
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 price target.
08-14 23:51
Galectin Therapeutics Q2 EPS $(0.12) Beats $(0.16) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 40 percent increase over losses of $(0.20) per share from
08-14 20:09
Galectin Therapeutics Secures $10M Credit Line for Growth
The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On July ...
07-09 20:16
HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6
HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces Price Target of $6.
06-17 19:26
Galectin Therapeutics Highlights Belapectin’s Potential in Liver Disease
The latest announcement is out from Galectin Therapeutics ( ($GALT) ). On June ...
06-17 00:28
Galectin Therapeutics Q1 EPS $(0.15) Beats $(0.20) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 21.05 percent increase over losses of $(0.19) per share
05-15 20:11
Galectin Therapeutics Issues Presentation Highlighting Its Focused Pipeline, MASH Cirrhosis And Oncology, Developing Galectin-Based Therapeutics To Improve The Lives Of Patients With Chronic Liver Diseases And Cancer
https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18
05-12 20:21
H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeuti...
04-02 18:17
Galectin Therapeutics Unveils Promising NAVIGATE Trial Results
An announcement from Galectin Therapeutics ( ($GALT) ) is now available. On Jan...
01-24 00:50
